Research summary
Dr. Ma Luo is a renowned scientist whose research focuses on understanding the mechanisms of resistance and susceptibility to HIV infection. She is particularly interested in the interplay between host genetics and viruses such as HIV, influenza, and SARS-CoV-2.
Currently, Dr. Luo is leading two major research programs. The first program is focused on evaluating and optimizing a novel HIV vaccine targeting sequences surrounding the 12 protease cleavage sites. This vaccine, known as the PCS vaccine, has the potential to revolutionize HIV prevention efforts by providing a new approach to immunization.
The second research program investigates the role of FREM1/TILRR mediated inflammation in susceptibility to HIV infection, as well as in severe responses to SARS-CoV-2 and H1N1 infection. Dr. Luo and her team are working to uncover the molecular mechanisms of this inflammation and how it contributes to viral infection and disease severity.
Dr. Luo's research has broad implications for improving global health by developing new vaccines and therapies for HIV, influenza, and other viral infections. Her work is based on a multidisciplinary approach that includes genetic analysis, molecular biology, biochemistry, and bioinformatics. Dr. Luo is a leading figure in the field of medical microbiology and infectious diseases, and her contributions have been recognized with numerous awards and accolades throughout her career.